Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA vs. the Vaxigrip® Inactivated Influenza Split Vaccine Manufactured by Sanofi Pasteur, France, in Volunteers Aged 18-60 Years

NCT05297994 is registered in ClinicalTrials.gov with St. Petersburg Research Institute of Vaccines and Sera as lead sponsor.

NCT NCT05297994
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297994 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA vs. the Vaxigrip® Inactivated Influenza Split Vaccine Manufactured by Sanofi Pasteur, France, in Volunteers Aged 18-60 Years
Lead sponsor
St. Petersburg Research Institute of Vaccines and Sera
Phase
Phase 2
Overall status
Completed
Start date
October 24, 2016
Completion date
March 9, 2017
Enrollment
400 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza